WALTHAM, Mass., Oct. 22, 2018 /PRNewswire/ -- Naveris, Inc., a private biotechnology company developing blood tests for earlycancer detection, congratulates Bhisham Chera, M.D. and Gaorav Gupta, M.D., Ph.D., scientific advisors and co-chairs of its Scientific Advisory Board, and announces the presentation of clinical trial data at the American
Dr. Chera's and Dr. Gupta's late-breaking abstract (LBA-6) has been selected for presentation in a special late-breaking session by a panel of peer reviewers, and as one of 10 top-rated studies that will be highlighted in the press program for the 2018 ASTRO Annual Meeting. Dr. Chera will deliver a platform presentation entitled "Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-associated Oropharyngeal Cancer" at the annual meeting on Tuesday, October 23, 2018.
Naveris, Inc., is the sole developer and provider of NavDx, a liquid biopsy blood test that detects Human Papilloma Virus (HPV)-associated head and neck cancers in patients. NavDx has been demonstrated to detect early recurrences in patients before they would be identified in current clinical practice.
Dr. Chera's platform presentation:Date & Time: Tuesday, October 23, 2018, at 7:45 a.m. (CT)Title: Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-associated Oropharyngeal CancerLocation: San Antonio Convention and Exhibition Center, San Antonio, TX.
About Naveris, Inc.
Naveris, Inc. (https://www.naveris.com) is a private biotechnology company focused on developing blood tests for early cancer detection. For additional information, email firstname.lastname@example.org.
Media contact: Charlotte Cooper email@example.com 833-628-3747
View original content:http://www.prnewswire.com/news-releases/naveris-congratulates-scientific-advisors-bhisham-chera-and-gaorav-gupta-on-presentation-of-clinical-data-at-the-2018-astro-annual-meeting-300735063.html
SOURCE Naveris, Inc.
Subscribe to our Free Newsletters!